Genital Herpes - Epidemiology Forecast - 2032

Genital Herpes - Epidemiology Forecast - 2032

DelveInsight’s ‘Genital Herpes disease - Epidemiology Forecast to 2032’ report delivers an in-depth understanding of Genital Herpes, historical and forecasted epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

Geography Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

China

Study Period: 2019-2032

Genital Herpes understanding

The DelveInsight’s Genital Herpes epidemiology report gives a thorough understanding of Genital Herpes by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Genital Herpes is a chronic sexually transmitted infection (STI) characterized by recurrent, self-limited genital ulcers caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). It can cause blisters and open sores (lesions) in the genital area, but it can also be asymptomatic, meaning a person does not show symptoms.

Genital herpes can be asymptomatic or have mild symptoms that go unrecognized. When symptoms occur, genital herpes is characterized by one or more genital or anal blisters or ulcers. Additionally, symptoms of a new infection often include fever, body aches, and swollen lymph nodes. After an initial episode, which can be severe, symptoms may recur. Genital herpes caused by HSV-1 typically does not recur frequently. With HSV-2, recurrent symptoms are common; however, recurrences are often less severe than the first episode and tend to decrease over time. The laboratory diagnosis of acute genital HSV infection or asymptomatic virus shedding is made via direct viral detection. The method of choice is the demonstration of viral genomes in the skin or mucous membrane swabs using the polymerase chain reaction (PCR). It is rightly regarded as the gold standard of diagnosis in many laboratories.

Genital Herpes Epidemiology

The Genital Herpes epidemiology division provides insights about historical and current Genital Herpes patient pool and forecasted trends for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology scenario in the 8MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China from 2019 to 2032.

In 2021, the total diagnosed Genital Herpes cases per year was 1.6 million cases in the 8MM which are expected to grow during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology [segmented as Prevalent HSV infected cases, Symptomatic Genital Herpes cases per year, Gender-specific cases of Genital Herpes, Diagnosed Genital Herpes cases per year, Total recurrent cases of Genital Herpes, and Treated patient pool of Genital Herpes] in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan and China from 2019 to 2032.

Country Wise- Genital Herpes Epidemiology

The epidemiology segment also provides the Genital Herpes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

KOL- Views

To keep up with the current Genital Herpes patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Genital Herpes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

The report covers a descriptive overview of Genital Herpes, explaining its causes, symptoms, pathophysiology, and genetic basis.

The report provides insight into the 8MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

The report assesses the selected cancer types risk and burden and highlights the unmet needs of Genital Herpes.

The report helps to recognize the growth opportunities in the 8MM concerning the patient population.

The report provides the segmentation of the Genital Herpes epidemiology by Prevalent HSV infected cases, Symptomatic Genital Herpes cases per year, Gender-specific cases of Genital Herpes, Diagnosed Genital Herpes cases per year, Total recurrent cases of Genital Herpes, and Treated patient pool of Genital Herpes in the 8MM.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition

A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Genital Herpes.

Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Genital Herpes Report Key Strengths

11 Years Forecast

8MM Coverage

Genital Herpes Epidemiology Segmentation

Key Questions

Epidemiology Insights:

What are the key factors driving the epidemiology trend for eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?

What is the historical Genital Herpes patient pool in eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?

What would be the forecasted patient pool of Genital Herpes in eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?

Where will be the growth opportunities in the 8MM concerning the patient population about Genital Herpes?

What are the key findings pertaining to the Genital Herpes epidemiology across the 8MM and which country will have the highest number of diagnosed Genital Herpes cases during the study period (2019–2032)?

At what CAGR the patient population is expected to grow by 8MM during the forecast period (2019-2032)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the Genital Herpes market

To understand the future market competition in the Genital Herpes market and Insightful review of the key unmet needs

Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.

Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes therapeutics in each of the markets covered

To understand the future market competition in the Genital Herpes market